ISSN: 2155-6105

Journal de recherche et de thérapie en toxicomanie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Indice source CAS (CASSI)
  • Index Copernic
  • Google Scholar
  • Sherpa Roméo
  • Ouvrir la porte J
  • JournalSeek de génamique
  • Clés académiques
  • JournalTOC
  • SécuritéLit
  • Infrastructure nationale du savoir de Chine (CNKI)
  • Bibliothèque de revues électroniques
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

Adding E-Cigarettes to Specialist Stop-Smoking Treatment: City of London Pilot Project

Hajek P, Corbin L, Ladmore D and Spearing E

Rationale: E-cigarettes (EC) are increasingly popular among smokers who want to limit the risks smoking poses to their health. There is some evidence that they facilitate long-term smoking cessation and are safe to use over short to mid-term. UK stop-smoking service (SSS) which provides free medications and support to smokers seeking help is currently seeing a reduction in the number of clients as rather than attending stop-smoking clinics, smokers prefer to use EC. Stop smoking medications are more effective when used with motivational support than when used unsupported. If SSS included EC in their treatment options, this could improve EC efficacy and enhance SSS reach.

Setting: We piloted the inclusion of free EC with 4-week supply of refills in routine SSS treatment offered to smokers living or working in the City of London. Census was taken after 100 smokers were offered EC.

Results: The total of 69 (69%) of smokers accepted EC and 45 (65%) of this group achieved biochemically validated abstinence at 4 weeks. Of smokers not accepting the offer of EC, 14 (45%) were validated abstainers at 4 weeks (Χ2 =3.53, p =.06). All successful quitters in the EC group reported using EC on most days throughout their quit attempt. Among this group, 31 (45%) smokers did not use or stopped using other stop-smoking medications. Client feedback was highly positive. Among smokers who accepted EC and achieved abstinence, all used EC at the end of treatment. Smokers using varenicline plus EC had a higher success rate (85%) than smokers using EC only (54%; X2=4.99, p=0.03).

Conclusion: Offering EC as an addition to the standard stop-smoking service may increase service appeal, costeffectiveness, and efficacy.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.